Nebivolol Medreg (Nebivolol)

Nebivolol selectively blocks β1‑adrenergic receptors, decreasing heart rate and contractility. At the same time, it stimulates endothelial nitric oxide release, causing vasodilation. This combined effect lowers blood pressure while supporting better blood flow without significant β2‑receptor blockade.

The appropriate dose of Nebivolol Medreg is determined by the prescribing healthcare professional based on the individual’s clinical condition, response to therapy, and any co‑existing medical issues. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Nebivolol’s pregnancy category is listed as unknown. It should only be used during pregnancy or lactation when the potential benefits justify the possible risks to the fetus or infant. Healthcare providers must evaluate each case individually.

To request Nebivolol Medreg, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nebivolol is a highly β1‑selective blocker with additional nitric‑oxide‑mediated vasodilation, which can result in fewer metabolic side effects and better tolerance compared with non‑selective beta blockers. Its dual mechanism may offer superior blood‑pressure control while preserving peripheral circulation.

Nebivolol Medreg tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children.

Nebivolol Medreg is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include severe bradycardia, marked hypotension, heart block, bronchospasm in patients with reactive airway disease, and rare allergic reactions such as angio‑edema. Patients should seek immediate medical attention if they experience fainting, rapid weight gain, swelling, or difficulty breathing.

Nebivolol is contraindicated in patients with known hypersensitivity to nebivolol or any excipients, those with severe bradycardia (heart rate <50 bpm), second‑ or third‑degree atrioventricular block without a pacemaker, and individuals with uncompensated heart failure or cardiogenic shock.